NO743433L - - Google Patents
Info
- Publication number
- NO743433L NO743433L NO743433A NO743433A NO743433L NO 743433 L NO743433 L NO 743433L NO 743433 A NO743433 A NO 743433A NO 743433 A NO743433 A NO 743433A NO 743433 L NO743433 L NO 743433L
- Authority
- NO
- Norway
- Prior art keywords
- strain
- serum
- influenza virus
- virus
- resistant
- Prior art date
Links
- 210000002966 serum Anatomy 0.000 claims description 57
- 241000700605 Viruses Species 0.000 claims description 35
- 241000712461 unidentified influenza virus Species 0.000 claims description 35
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 32
- 239000003112 inhibitor Substances 0.000 claims description 31
- 235000013601 eggs Nutrition 0.000 claims description 26
- 238000010790 dilution Methods 0.000 claims description 20
- 239000012895 dilution Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 16
- 229960000458 allantoin Drugs 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 241000700199 Cavia porcellus Species 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 6
- 229940124873 Influenza virus vaccine Drugs 0.000 claims description 3
- 230000002238 attenuated effect Effects 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 description 13
- 241000283073 Equus caballus Species 0.000 description 8
- 241000282339 Mustela Species 0.000 description 7
- 229960003971 influenza vaccine Drugs 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000001888 Peptone Substances 0.000 description 5
- 108010080698 Peptones Proteins 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 235000019319 peptone Nutrition 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000035931 haemagglutination Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 244000309464 bull Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000011521 glass Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 229940037525 nasal preparations Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 241000353621 Eilat virus Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000007799 cork Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003067 hemagglutinative effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960000233 throat preparations Drugs 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Virology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/401,335 US3953592A (en) | 1973-09-27 | 1973-09-27 | Live influenza virus vaccines and preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO743433L true NO743433L (xx) | 1975-04-28 |
Family
ID=23587327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO743433A NO743433L (xx) | 1973-09-27 | 1974-09-24 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US3953592A (xx) |
| JP (1) | JPS5058223A (xx) |
| AT (1) | AT331978B (xx) |
| BE (1) | BE819865A (xx) |
| CA (1) | CA1030450A (xx) |
| CH (1) | CH595447A5 (xx) |
| CS (1) | CS203080B2 (xx) |
| DD (1) | DD114966A5 (xx) |
| DE (1) | DE2445819A1 (xx) |
| DK (1) | DK508274A (xx) |
| ES (1) | ES430415A1 (xx) |
| FI (1) | FI278774A (xx) |
| FR (1) | FR2245376B1 (xx) |
| GB (1) | GB1461188A (xx) |
| HU (1) | HU169383B (xx) |
| IE (1) | IE40180B1 (xx) |
| IL (1) | IL45589A (xx) |
| LU (1) | LU70998A1 (xx) |
| NL (1) | NL7411746A (xx) |
| NO (1) | NO743433L (xx) |
| SE (1) | SE429405B (xx) |
| ZA (1) | ZA745571B (xx) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6042209B2 (ja) * | 1974-05-31 | 1985-09-20 | 北里研究所（社団法人） | インフルエンザウイルスの新鮮分離株を発育鶏卵へ短期間で順化させる方法 |
| US4318903A (en) * | 1978-07-12 | 1982-03-09 | Smithkline-Rit | Live influenza virus vaccine and the preparation thereof |
| US4278662A (en) * | 1979-10-16 | 1981-07-14 | Smith Kline - Rit | Attenuated influenza type A virus vaccine |
| JPS59163313A (ja) * | 1983-03-09 | 1984-09-14 | Teijin Ltd | 経鼻投与用ペプチドホルモン類組成物 |
| US4783411A (en) * | 1984-10-22 | 1988-11-08 | Janis Gabliks | Influenza-A virus vaccine from fish cell cultures |
| NZ224422A (en) * | 1987-05-05 | 1990-11-27 | Molecular Eng Ass | Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid |
| US6398774B1 (en) | 1999-09-29 | 2002-06-04 | Heska Corporation | Intranasal delivery system |
| US7678087B2 (en) * | 1999-09-29 | 2010-03-16 | Heska Corporation | Equine intranasal delivery system |
| CA2756206A1 (en) | 2009-03-27 | 2010-09-30 | Academia Sinica | Methods and compositions for immunization against virus |
| TWI537385B (zh) | 2010-11-04 | 2016-06-11 | 中央研究院 | 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法 |
-
1973
- 1973-09-27 US US05/401,335 patent/US3953592A/en not_active Expired - Lifetime
-
1974
- 1974-08-28 CH CH1173374A patent/CH595447A5/xx not_active IP Right Cessation
- 1974-08-29 CA CA208,125A patent/CA1030450A/en not_active Expired
- 1974-08-30 ZA ZA00745571A patent/ZA745571B/xx unknown
- 1974-09-04 IL IL45589A patent/IL45589A/en unknown
- 1974-09-04 NL NL7411746A patent/NL7411746A/xx not_active Application Discontinuation
- 1974-09-13 FR FR7431029A patent/FR2245376B1/fr not_active Expired
- 1974-09-13 BE BE148474A patent/BE819865A/xx not_active IP Right Cessation
- 1974-09-21 JP JP49109440A patent/JPS5058223A/ja active Pending
- 1974-09-24 NO NO743433A patent/NO743433L/no unknown
- 1974-09-24 CS CS746552A patent/CS203080B2/cs unknown
- 1974-09-25 FI FI2787/74A patent/FI278774A/fi unknown
- 1974-09-25 LU LU70998A patent/LU70998A1/xx unknown
- 1974-09-25 DE DE19742445819 patent/DE2445819A1/de not_active Ceased
- 1974-09-26 HU HURE565A patent/HU169383B/hu unknown
- 1974-09-26 IE IE1994/74A patent/IE40180B1/xx unknown
- 1974-09-26 DD DD181344A patent/DD114966A5/xx unknown
- 1974-09-26 SE SE7412113A patent/SE429405B/sv unknown
- 1974-09-26 AT AT776074A patent/AT331978B/de active
- 1974-09-26 ES ES430415A patent/ES430415A1/es not_active Expired
- 1974-09-26 GB GB4184974A patent/GB1461188A/en not_active Expired
- 1974-09-26 DK DK508274A patent/DK508274A/da unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5058223A (xx) | 1975-05-21 |
| US3953592A (en) | 1976-04-27 |
| ZA745571B (en) | 1975-09-24 |
| CS203080B2 (en) | 1981-02-27 |
| GB1461188A (en) | 1977-01-13 |
| CH595447A5 (xx) | 1978-02-15 |
| SE429405B (sv) | 1983-09-05 |
| IE40180B1 (en) | 1979-03-28 |
| IE40180L (en) | 1975-03-27 |
| CA1030450A (en) | 1978-05-02 |
| FI278774A (xx) | 1975-03-28 |
| HU169383B (xx) | 1976-11-28 |
| FR2245376A1 (xx) | 1975-04-25 |
| DE2445819A1 (de) | 1975-04-10 |
| DK508274A (xx) | 1975-06-02 |
| NL7411746A (nl) | 1975-04-02 |
| ATA776074A (de) | 1975-12-15 |
| AU7330674A (en) | 1976-03-18 |
| BE819865A (fr) | 1975-03-13 |
| DD114966A5 (xx) | 1975-09-05 |
| FR2245376B1 (xx) | 1978-07-28 |
| IL45589A (en) | 1977-05-31 |
| IL45589A0 (en) | 1974-11-29 |
| AT331978B (de) | 1976-09-10 |
| LU70998A1 (xx) | 1975-03-06 |
| SE7412113L (xx) | 1975-04-01 |
| ES430415A1 (es) | 1977-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6704964B2 (ja) | ブタ流行性下痢ウイルスワクチン | |
| EP1144001B1 (de) | Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation | |
| AU763210B2 (en) | Novel influenza virus vaccine composition | |
| JP3545418B2 (ja) | インフルエンザの新規組換え温度感受性変異体 | |
| US4009258A (en) | Influenza vaccine containing a recombinant, antigenically hybridized virus and method of using the same | |
| US9505806B2 (en) | DNA vaccine, method of inducing the immune response, method of immunisation, antibodies specifically recognising the H5 haemagglutinin of an influenza virus and use of the DNA vaccine | |
| US20140286981A1 (en) | Broadly reactive mosaic peptide for influenza vaccine | |
| CN102406932A (zh) | 用于治疗/预防流感病原体在物种间传播的疫苗的用途 | |
| NO743433L (xx) | ||
| Xu et al. | Chimeric Newcastle disease virus-like particles containing DC-binding peptide-fused haemagglutinin protect chickens from virulent Newcastle disease virus and H9N2 avian influenza virus challenge | |
| Zheng et al. | A single immunization with HA DNA vaccine by electroporation induces early protection against H5N1 avian influenza virus challenge in mice | |
| US4318903A (en) | Live influenza virus vaccine and the preparation thereof | |
| Klausberger et al. | Off-target effects of an insect cell-expressed influenza HA-pseudotyped Gag-VLP preparation in limiting postinfluenza Staphylococcus aureus infections | |
| US20220096620A1 (en) | Foot-and-mouth disease virus-like particle antigen, and vaccine composition, preparation method, and application thereof | |
| US7758867B2 (en) | Attenuated influenza virus and a live vaccine comprising the same | |
| CN106117322A (zh) | 重组流感病毒血凝素(ha)抗原蛋白和含其的疫苗 | |
| CN100410378C (zh) | 编码禽流感血凝素的基因及其植物表达载体和应用 | |
| CN104804099B (zh) | 一种重组h9n2亚型禽流感加强型多表位疫苗 | |
| EP0027249B1 (fr) | Procédé de préparation de souches vaccinales de virus de l'influenza de type A, souche vaccinale et vaccin la contenant | |
| CN107129527A (zh) | 一种马链球菌兽疫亚种保护性抗原hp0623及其制备方法 | |
| US3962423A (en) | Live influenza type B virus vaccines and preparation thereof | |
| US11547754B2 (en) | H5 avian influenza vaccine strain which differentiates infected from vaccinated animals, preparation method therefor, and application | |
| US3897549A (en) | Herpes simplex type 2 virus vaccine and method of production and use | |
| US9771564B2 (en) | Influenza virus | |
| CN110917343A (zh) | 一种新城疫与传染性法氏囊病二联亚单位疫苗 |